Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:The global impact of the COVID-19 pandemic on the management and course of chronic urticaria
Authors:ID Kocatürk, Emek (Author)
ID Salman, Andaç (Author)
ID Cherrez-Ojeda, Ivan (Author)
ID Criado, Paulo Ricardo (Author)
ID Peter, Jonny (Author)
ID Comert-Ozer, Elif (Author)
ID Abuzakouk, Mohamed (Author)
ID Câmara Agondi, Rosana (Author)
ID Al-Ahmad, Mona (Author)
ID Altrichter, Sabine (Author)
ID Bizjak, Mojca, Klinika Golnik (Author)
ID Košnik, Mitja, Klinika Golnik, Medicinska fakulteta UL (Author)
Files:URL URL - Source URL, visit https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.14687
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
Keywords:chronic urticaria, pandemics, omalizumab, cyclosporine, COVID-19, SARS-CoV-2, UCARE, treatment
Publication status:In print
Publication version:Author Accepted Manuscript
Place of publishing:Velika Britanija
Publisher:John Wiley & Sons
Year of publishing:2020
Number of pages:str. [1-39]
Numbering:Vol. 75, iss.
PID:20.500.12556/DiRROS-12897 New window
UDC:616-097
ISSN on article:1398-9995
DOI:10.1111/ALL.14687 New window
COBISS.SI-ID:42049795 New window
Copyright:John Wiley & Sons
Note:Nasl. z nasl. zaslona; Soavtorja iz Slovenije: Mojca Bizjak, Mitja Košnik; Opis vira z dne 10. 12. 2020;
Publication date in DiRROS:14.12.2020
Views:2180
Downloads:535
Metadata:XML DC-XML DC-RDF
:
KOCATÜRK, Emek, SALMAN, Andaç, CHERREZ-OJEDA, Ivan, CRIADO, Paulo Ricardo, PETER, Jonny, COMERT-OZER, Elif, ABUZAKOUK, Mohamed, CÂMARA AGONDI, Rosana, AL-AHMAD, Mona, ALTRICHTER, Sabine, BIZJAK, Mojca and KOŠNIK, Mitja, 2020, The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy [online]. 2020. Vol. 75, p. 1–39. [Accessed 26 March 2025]. DOI 10.1111/ALL.14687. Retrieved from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.14687
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Allergy
Publisher:Blackwell
ISSN:1398-9995
COBISS.SI-ID:515009305 New window

Secondary language

Language:Undetermined
Keywords:kronična urtikarija, pandemije, omalizumab, ciklosporin, covid-19, SARS-CoV-2, UCARE, zdravljenje


Back